Effect of active immunotherapy with lymphocytes on repeated implantation failure

doi:10.3969/j.issn.2095-4344.2014.51.015

Abstract

Abstract:

BACKGROUND: There are many reports addressing the good effect of active immunotherapy on repeated miscarriage, but the effect of active immunotherapy on repeated implantation failure needs to be confirmed by further studies.
OBJECTIVE: To study the effect of active immunotherapy with lymphocytes on repeated implantation failure in in vitro fertilization-embryo transfer．
METHODS: Active immunotherapy with lymphocytes was done in 52 repeated implantation failure patients lacking blocking antibodies. Repeated implantation failure patients were divided into two groups: study group (74 cycles): active immunotherapy was done and blocking antibodies turned positive before embryo transfer; control group (92 cycles): active immunotherapy was not done before embryo transfer. The pregnancy outcome was compared between two groups.
RESULTS AND CONCLUSION: After the active immunotherapy with lymphocytes, the positive rate of blocking antibodies was 92% in repeated implantation failure patients. The pregnancy rate and implantation rate of study group were significantly higher than those of the control group (P < 0.05), but there was no significant difference in the miscarriage rate between two groups (P > 0.05). So the active immunotherapy with lymphocytes in repeated implantation failure patients may be helpful to improve the rate of pregnancy in following embryo transfer.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: transplantation, antibodies, pregnancy, lymphocytes, immune system

CLC Number:

R318

Zhao Fang, Lv Yu-zhen, Wang Juan, Jiang Yi, Tian Ke-ke. Effect of active immunotherapy with lymphocytes on repeated implantation failure[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(51): 8281-8285.

Figures/Tables 2

References

[1]Harton G, Braude P, Lashwood A, et al. ESHER PGD consortium best practice guidelines for organization of a PGD centre for PGD/ preimplantation genetic screening. Hum Reprod. 2011;26(1):14-24.
[2]Potdar N, Gelbaya T, Nardo LG. Endometrial injury to overcome recurrent embryo implantation failure: a systematic review and meta-analysis. Reprod Biomed Online. 2012;25(6): 561-571.
[3]全松,陈雷宁,高瑞花,等.胚胎反复种植失败的处理研究进展[J].广东医学,2010,31(19):2475-2477.
[4]Simon A, Laufer N. Repeated implantation failure: clinical approach. Fertil Steril. 2012;97(5):1039-1043
[5]DeLoia JA, Stewart-Akers AM, Brekosky J, et al. Effects of exogenous estrogen on uterine leukocyte recruitment. Fertil Steril. 2002;77(3):548-554.
[6]Beydoun H, Saftlas AF. Association of human leucocyte antigen sharing with recurrent spontaneous abortions. Tissue Antigens. 2005;65(2):123-135.
[7]Makrigiannakis A, Petsas G, Toth B, et al. Recent advances in understanding immunology of reproduetive failure. Reprod Immunol. 2011;90:96-104.
[8]郑妍,何庭宇,何茜冬,等.人类白细胞抗原基因多肽性与不明原因反复流产免疫治疗妊娠结局的初步探讨[J].生殖与避孕,2010, 30(3):174-176.
[9]张建平,林其德,李大金.复发性流产的诊断及治疗[J].现代妇产科进展,2006,15(7):481-492.
[10]方伟祯,蔡振华,谢晓英.封闭抗体检测与反复自然流产患者主动免疫治疗的相关性分析[J].中国微生态学杂志,2014,26(9): 1059-1061.
[11]李大金,余江,朱影,等.母-胎免疫识别低下型反复自然流产配偶淋巴细胞免疫疗法的改进[J].上海免疫学杂志,2003,23(6): 393-395.
[12]Nyboe Andersen A, Goossens V, Bhattacharya S, et al. Assisted reproductive technology and intrauterine inseminations in Europe, 2005. Results generated from European registers by ESHRE. Hum Reprod. 2009;24(6): 1267-1287.
[13]邱丽华,林其德.调节性T淋巴细胞与原因不明复发性流产的相关性研究[J].中华妇产科杂志,2004,39(12):816-818.
[14]Yang H, Qiu L, Chen G, et al. Proportional change of CD4+ CD25 + regulatory T cells after lymphocyte therapy in un-explained recurrent spontaneous abortion patients. Fertil Steril. 2009;92(1):301-305.
[15]沈伶,卢焕霞,胡瑞霞,等.两种免疫治疗方法治疗封闭抗体阴性复发性流产患者的疗效观察[J].新医学,2011,42(6):402-405.
[16]彭婀娜.姚若进.不明原因复发性流产主动免疫治疗前后封闭抗体的变化及其意义[J].实用妇产科杂志,2010,26:773-775.
[17]赖有行,李正梅,詹新林,等.主动免疫联合中药治疗封闭抗体不足性反复自然流产的临床观察[J].中国妇幼保健,2014, 29(21): 3486-3488.
[18]杨章莉,周春慧,李新蓉,等.淋巴细胞主动免疫联合地屈孕酮治疗封闭抗体阴性所致复发性流产的临床观察[J].生殖医学杂志, 2014,23(2):128-130.
[19]伍金华,黄胜起,谢志威,等.原因不明复发性流产主动免疫治疗前后CD3+PD-1+T细胞表达水平研究[J].中华实用诊断与治疗杂志, 2014,28(8):747-749.
[20]Christiansen OB, Nielsen HS, Kolte AM, et al. Future direction of failed implantation and recurrent miscarriage research. Reprod Biomed Online. 2006;13(1):71-83.
[21]Stern C, Chamley L. Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and recurrent miscarriage. Reprod Biomed Online. 2006; 13(1):29-37.
[22]Kling C, Schmutzler A, Wilke G, et al. Two-year outcome after recurrent implantation failure: prognostic factors and additional interventions. Arch Gynecol Obstet. 2008;8(2): 135-142.
[23]彭桂元,伍招娣,黄向红,等.主动免疫治疗不明原因反复自然流产疗效的循证医学评价[J].中国医学工程杂志,2006,14(5): 489-493.
[24]Szpakowski A, Malinowski A, Glowacka E, et al. The influence of paternal lymphocyte immunization on the balance of Th1/ Th2 type reactivity in women with unexplained recurrent spontaneous abortion. Ginekol Pol. 2000;71(6):586-592.
[25]李大金,李超荆.原发性反复自然流产的白细胞免疫治疗[J].生殖与避孕,1995,15(6):457-458.
[26]陶淑贞.淋巴细胞免疫治疗反复自然流产140例分析[J].江苏卫生保健,2008,10(5):42-43.
[27]林其德,邱丽华.免疫型复发性流产的发病机制及诊断和治疗[J].上海交通大学学报(医学版),2009,29(11):1275-1278.
[28]娄华,王兴玲,王雪梅,等.反复胚胎植入失败患者主动免疫治疗前后封闭抗体的检测及其意义[J].现代免疫学,2013,33(1):52-55.
[29]Clark DA, Gorczynski RM, Blajchman MA, Transfusion- related immunomodulaton due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion. 2008;48(5): 814-821.
[30]邹琳,彭彩玲,许丽华,等.321 例复发性流产患者采用丈夫或无关个体淋巴细胞免疫治疗的临床分析[J].中国妇幼保健,2014, 29(24):3951-3952.
[31]佘宏,胡艳秋,吕芳,等.复发性自然流产患者淋巴细胞主动免疫治疗的临床分析[J].中华妇幼临床医学杂志(电子版),2014,10(5): 98-101.
[32]黄华英,孙鸿燕,廖运梅.淋巴细胞主动免疫治疗对反复自然流产的疗效分析及其护理策略[J].中华妇幼临床医学杂志(电子版), 2012,8(3):255-257.
[33]Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol. 2012;67(4):296-304.
[34]Clark DA. Shall we properly re-examine the status of allogeneic therapy for recurrent early pregnancy failure. Am J Reprod Immunol. 2004;51(1):7-15.
[35]Fan X, Wang Z, Ji P, et al. rgpA DNA vaccine induces antibody response and prevents alveolar bone loss in experimental peri-implantitis. J Periodontol. 2013;84(6): 850-856.
[36]Liu Y, Wang Q, Kleinschmidt-DeMasters BK, et al. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol. 2007;81(2):149-162.
[37]Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003;63(24):8996-9006.
[38]Rao J, Seshagiri PB, Shetty G, et al. Active immunization against riboflavin carrier protein results in peri-implantation embryonic loss leading to pregnancy termination in rats: use of alternate adjuvants. Indian J Exp Biol. 2000;38(9):863-872.
[39]Steck T. Immunotherapy for prevention of abortion and for improving implantation in extracorporeal fertilization. Zentralbl Gynakol. 2001;123(6):357-360.
[40]Baines MG, Duclos AJ, de Fougerolles AR, et al. Immunological prevention of spontaneous early embryo resorption is mediated by non-specific immunosimulation. Am J Reprod Immunol. 1996;35(1):34-42.